CliffBio
small molecule

DAKLINZA

DACLATASVIR DIHYDROCHLORIDE

Loss of exclusivityJune 2031latest FDA-listed patent expiry
CompanyBristol-Myers Squibb →View the full company profile on CliffBio

Drug detail

Brand nameDAKLINZA
Active ingredientDACLATASVIR DIHYDROCHLORIDE
StrengthEQ 60MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2015
Marketing statusDISCN

Listed patents

PatentExpiresType
8629171June 2031substance, product
8329159July 2029substance
8642025August 2027substance, product
8900566August 2027use U-1724
9421192August 2027substance

More from Bristol-Myers Squibb

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DAKLINZA patent cliff — loss of exclusivity June 2031 | CliffBio